The Frontotemporal Dementia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Frontotemporal Dementia: An Overview
Frontotemporal dementia (FTD) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain areas. In this disorder, portions of these lobes shrink (atrophy). The degeneration of the frontotemporal lobe is primarily triggered due to proteins involvement TDP43 and tau, which directly outbreaks the damage on the temporal and frontal lobes of the brain.
Frontotemporal Dementia signs and symptoms vary, depending upon the portion of the brain affected. Some people with frontotemporal dementia undergo dramatic changes in their personality and become socially inappropriate, impulsive, or emotionally indifferent, while others lose the ability to use language.
Frontotemporal Dementia Market Key Facts
-
Among the Frontotemporal Dementia patients, males show a higher proportion of prevalence as compared to females in the 7MM
-
As per the National Organization for Rare Disorder 2019, Frontotemporal degeneration is estimated to affect about 50,000–60,000 people in the United States.
-
As per the study conducted by Juan Joseph Young et al. 2017, in the USA, the prevalence of FTD between the ages of 45–65 years ranged from 15 to 22 per 100,000 people, with incidence estimates ranging from 2.7 to 4.1 per 100,000 members in the same age range.
Frontotemporal Dementia Market
Even though various therapies are available for the management of symptoms of Frontotemporal Dementia, they have some limitations such as a high dose of these therapies, which may cause life-threatening adverse effects. So, there is a high unmet need for novel therapies that can overcome these limitations. In addition to this, there is no effective therapy for cognitive complaints in FTD, which frequently involve executive function, memory, and language.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Frontotemporal Dementia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Frontotemporal Dementia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Frontotemporal Dementia Epidemiology
The epidemiology section covers insights into the historical and current Frontotemporal Dementia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.
Frontotemporal Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Frontotemporal Dementia market or expected to get launched during the study period. The analysis covers the Frontotemporal Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Frontotemporal Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Frontotemporal Dementia Therapeutics Analysis
Frontotemporal Dementia (FTD) is an underdiagnosed group of neurological syndromes comprising multiple variants with distinct neurobiological profiles and presentations. But the Frontotemporal Dementia market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also the expected launch of emerging therapies.
Companies across the globe are working toward the development of new treatment therapies for frontotemporal dementia, but few companies have made it to the clinical stage of development.
Some of the key companies in the Frontotemporal Dementia market include:
-
TauRx Therapeutics
-
Alector
-
Neurimmune
-
Biogen
And many others.
Frontotemporal Dementia Therapies covered in the report include:
-
LMTX
-
AL001
-
NI205
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Frontotemporal Dementia Competitive Intelligence Analysis
4. Frontotemporal Dementia Market Overview at a Glance
5. Frontotemporal Dementia Disease Background and Overview
6. Frontotemporal Dementia Patient Journey
7. Frontotemporal Dementia Epidemiology and Patient Population
8. Frontotemporal Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Frontotemporal Dementia Unmet Needs
10. Key Endpoints of Frontotemporal Dementia Treatment
11. Frontotemporal Dementia Marketed Products
12. Frontotemporal Dementia Emerging Therapies
13. Frontotemporal Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Frontotemporal Dementia Market Outlook (7 major markets)
16. Frontotemporal Dementia Access and Reimbursement Overview
17. KOL Views on the Frontotemporal Dementia Market.
18. Frontotemporal Dementia Market Drivers
19. Frontotemporal Dementia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/frontotemporal-dementia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
DelveInsight’s “Pars Plantis Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Pars Plantis market size, and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/